The USPTO’s Patent Trial and Appeal Board has refused to institute another inter partes review petition filed by Kyle Bass, this time against a Biogen patent for a method of treating multiple sclerosis
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
National groups for the UK and the Netherlands have flagged concerns with the choice of venue, following a formal complaint from Australia’s national group